Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.61 |
| ▸ | KCNN3 | Q9UGI6 | 14/20 | 0.46 |
| ▸ | KCNN1 | Q92952 | 2/20 | 0.46 |
| ▸ | KCNN2 | Q9H2S1 | 2/20 | 0.46 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.34 |
| ▸ | CCNT1 | O60563 | 3/20 | 0.33 |
| ▸ | CDK9 | P50750 | 3/20 | 0.33 |
| ▸ | CDK7 | P50613 | 2/20 | 0.33 |
| ▸ | CCNH | P51946 | 2/20 | 0.33 |
| ▸ | CDK4 | P11802 | 1/20 | 0.33 |
| ▸ | CCND1 | P24385 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21754101 | 0.81 | PDE10A (0.41) | PDE10AKCNN3DGAT1CCNT1CDK9 | |
| SCHEMBL22932762 | 0.81 | MEN1 (0.43) | PDE10AKCNN3DGAT1CCNT1CDK9 | |
| SCHEMBL24408174 | 0.77 | CCNT1 (0.51) | CCNT1CDK9CDK7CCNHCDK4 | |
| SCHEMBL22131142 | 0.77 | PRKAB2 (0.46) | PDE10AKCNN3KCNN1KCNN2DGAT1 | |
| SCHEMBL29344715 | 0.77 | PDE10A (0.67) | PDE10AKCNN3KCNN1KCNN2CCNT1 | |
| SCHEMBL29869 | 0.76 | PDE10A (1.00) | PDE10AKCNN3KCNN1KCNN2 | |
| SCHEMBL1290450 | 0.73 | PDE10A (0.67) | PDE10AKCNN3KCNN1KCNN2 | |
| SCHEMBL30974 | 0.73 | PDE10A (0.67) | PDE10AKCNN3KCNN1KCNN2DGAT1 | |
| SCHEMBL12952976 | 0.72 | PDE10A (0.61) | PDE10AKCNN3KCNN1KCNN2DGAT1 | |
| SCHEMBL14242902 | 0.72 | PDE10A (0.61) | PDE10AKCNN3KCNN1KCNN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090291945-A1 | CYSTEINE PROTEASE INHIBITORS | TEIJIN PHARMA LIMITED (JP) | 2009-11-26 | — | — | US | disclosed |
| US-20090291945-A1 | CYSTEINE PROTEASE INHIBITORS | TEIJIN PHARMA LIMITED (JP) | 2009-11-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090291945-A1 | CYSTEINE PROTEASE INHIBITORS | CTSE, SPINT2, CTSF | PDE10A 3095/4885KCNN3 3917/4885KCNN1 3565/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.